Drugs / ITU512
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06546670 | Aug 2024 → May 2028 expected | sickle cell disease | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ITU512 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06546670 ↗ |
| Modality | Small molecule | “ITU512 is an investigational, oral, low molecular weight (LMW) compound.” NCT06546670 ↗ |
| Route | Oral | “ITU512 is an investigational, oral, low molecular weight (LMW) compound.” NCT06546670 ↗ |